EUCTR2016-000049-30-ES进行中（未招募）1 期
A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NMIBC) patients with BCG-refractory CIS - Radiofrequency-Induced Thermochemotherapy Effect
Medical Enterprises Europe B.V0 个研究点目标入组 160 人开始时间: 2017年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patients with CIS, with or without coexisting papillary NMIBC, who either:
- •a. fail to achieve a disease-free status by 6 months after initial BCG therapy, with maintenance or re-induction at 3 months due to either persistent or rapidly recurrent disease, or
- •b. experience a worsening in NMIBC state following initial BCG therapy presenting with a new NMIBC instance, other than TaLG.
- •2. All clinical, intra-operative and pathological items for the EAU risk stratification must be documented including a bladder map.
- •3. Patients with papillary disease must have undergone a repeat TUR:
- •a. if the initial TUR was incomplete.
- •b. if there was no muscle in the specimen after the initial TUR (except in TaLG tumors).
- •c. in all T1 tumors. TUR of T1 sites must include muscle.
- •d. in all HG tumors > 3cm.
- •4. CT-IVU or IVU confirmation of absence of tumor(s) in the upper tract, kidney and ureters performed within 6 months before the treatment initiation in selected cases as recommended in latest EAU guidelines published prior to screening. If IVU protocol not available or contrast allergy/poor renal function preclude such imaging, then non-contrast CT or MRI of the abdomen/pelvis within the same timeframe will suffice.
- •5. Visual inspection to exclude urothelial carcinoma (UC) in the urethra during cystoscopy.
- •6. Biopsy of the prostatic urethra in male patients prior to recruitment to exclude UC of the prostatic urethra, in patients with:
- •a. tumor of trigone,
- •b. tumor of bladder neck, or
- •c. abnormal prostatic urethra
- •7. All patients must have urine cytology collected from either voided urine or bladder wash within the screening period prior to recruitment.
- •8. All patients must have prostatic urethral biopsies collected within the screening period prior to recruitment.
- •9. Age = 18 yrs.
- •10. Normal kidneys and ureters.
- •11. Pre-treatment hematology and biochemistry values within the limits:
- •a. Hemoglobin = 10 g/dl
- •b. Platelets = 150 x 109/L
- •c. WBC = 3.0 x 109/L
- •d. ANC = 1.5 x 109/L
- •e. Serum creatinine < 1.5 x ULN
- •f. SGOT < 1.5 x ULN
- •g. SGPT < 1.5 x ULN
- •h. Alkaline phosphatase < 1.5 x ULN
- •12. Negative pregnancy test for women of childbearing potential.
- •13. A life expectancy at least of the duration of the study (up to 13 months).
- •14. Patients unfit or unwilling to have a full or partial (if appropriate) cystectomy.
- •15. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Non-UC tumor of the urinary tract.
- •2. Upper tract and intramural tumors (e.g., in ostium).
- •3. Positive selective cytology from the upper tract.
- •4. History of stage > T1 UC.
- •5. Papillary tumor in repeat TUR in patients diagnosed with HG > 3cm and/or T1 in the initial TUR.
- •6. Papillary tumor = T1 in repeat TUR
- •7. Known or suspected reduced bladder capacity. Patients will have a US estimation of maximum bladder capacity or void spontaneously the maximum they can retain in their bladder, and this will be used to determine urine volume. A minimum volume of 250 ml is required.
- •8. Bleeding disorder.
- •9. Macrohematuria of = 250 RBC/uL or equivalent (e.g., > +++” erythrocytes in a dipstick analysis) within 4 weeks before treatment start.
- •10. Lactating women.
- •11. Women of childbearing potential unwilling or unable to use adequate contraception if sexually active.
- •12. More than a maintenance dose of oral corticosteroids (maintenance dose is defined as the same dose regimen over the past 6 months for a condition requiring continual corticosteroid treatment) or patients with an immunocompromised state for any reason.
- •13. More than low-dose methotrexate (>17.5 mg once a week).
- •14. Other malignancy within the past 5 years, except: non-melanomatous skin cancer cured by excision, surgically treated carcinoma in situ of the cervix or ductal CIS (DCIS)/lobular CIS (LCIS) of the breast or stable prostate cancer (under active surveillance or hormone control) with a life expectancy of more than 5 years.
- •15. Any known allergy (e.g., to MMC) or adverse event that would prevent a prospective study participant from receiving the study treatment.
- •16. Known untreated urethral strictural disease or bladder neck contracture or any other condition that may prevent catheterization with 21F catheter. Patients may undergo dilation or urethral incision before entering the study.
- •17. Bladder diverticula with cumulative diameter > 1cm or tumor in a diverticulum.
- •18. UTI at any time within 4 weeks before treatment start.
- •19. Significant urinary incontinence (spontaneous, requiring use of pads).
- •20. History of pelvic irradiation.
- •21. Patients with implanted electronic devices (such as cardiac pacemakers) unless they receive permission from their treating physician (e.g., cardiologist) and are monitored by a treating physician during the treatment session.
- •22. Participation in another study, unless discussed with and approved by the study manager
研究者
相似试验
进行中（未招募）
1 期
A study in non-muscle invasive bladder cancer (CIS with or without papillary tumors) patients that failed to be clean 6 months after BCG therapy, and then join the study to treated by radiofrequency (microwave) technique combined with hyperthermia and the chemotherapy drug, Mitomycin C.on-Muscle-Invasive Bladder CancerEUCTR2016-000049-30-ATMedical Enterprises Europe B.V160
进行中（未招募）
1 期
A study to about blinatumomab for patients with minimal residual disease (MRD) of acute lymphoblastic leukemiaPatients with minimal residual disease (MRD) positive B-precursor ALL with and without prior SCT documented after an interval of at least 8 days from last systemic chemo-therapy• at a level of =10-4 - <10-3 (molecular failure or molecular relapse) in an assay with a minimum sensitivity of 10-4 OR• at levels below 10-4 :o Positive <10-4, non quantifiable (MolNE1) ORo Positive <10-4 (MolNE2) OR• Presence of minimal residual disease (MRD), non quantifiable (MolNE3).MedDRA version: 21.1Level: LLTClassification code 10066104Term: Precursor B-lymphoblastic leukaemia acuteSystem Organ Class: 100000004864EUCTR2015-000733-76-DEGoethe-Universität Frankfurt, Universitätsklinikum, Med. Klinik II80
已完成
3 期
Effect of Tildrakizumab in Patients with Moderate-to-Severe Plaque PsoriasisCTRI/2023/06/053784Sun Pharmaceutical Industries Limited115
进行中（未招募）
1 期
Multicenter study on adults with chronic hepatitis C with cirrhosis to study the effects of boceprevir and pegylated interferon alfa-2b and ribaviriChronic Hepatitis CMedDRA version: 14.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 100000004862EUCTR2012-002772-13-ITMSD ITALIA S.R.L.58
招募中
3 期
A study to investigate the pharmacokinetics and safety of dupilumab in participants >=2 years to < 12 years of age with uncontrolled chronic spontaneous urticaria (CSU) or chronic inducible cold urticaria (CICU)JPRN-jRCT2031220733Tanaka Tomoyuki24